<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02451007</url>
  </required_header>
  <id_info>
    <org_study_id>PM1183-B-005-14-QT</org_study_id>
    <nct_id>NCT02451007</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors</brief_title>
  <official_title>Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization (QTc Duration) in Patients With Selected Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaMar</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmaMar</source>
  <brief_summary>
    <textblock>
      Study to assess the potential effects of lurbinectedin (PM01183) at a therapeutic dose on the
      duration of the QTc interval, measured by electrocardiograms (ECGs), to characterize the
      PM01183 plasma concentration/QTc relationship, and to explore related ECG parameters in
      patients with selected solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in QTcF (QT corrected according to Fridericia formula)</measure>
    <time_frame>Day 1 of cycle 1 and Day 1 of cycle 2</time_frame>
    <description>Difference in QT corrected by Fridericia's method (QTcF) between each scheduled post-dose ECG time point and baseline at Cycle 1 (ΔQTcF).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relationship ΔQTcF / PM01183 plasma concentration</measure>
    <time_frame>Day 1 of cycle 1 and Day 1 of cycle 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in response rate (RR)</measure>
    <time_frame>Day 1 of cycle 1 and Day 1 of cycle 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in heart rate</measure>
    <time_frame>Day 1 of cycle 1 and Day 1 of cycle 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in QRS interval</measure>
    <time_frame>Day 1 of cycle 1 and Day 1 of cycle 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in PR interval</measure>
    <time_frame>Day 1 of cycle 1 and Day 1 of cycle 2</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>A (lurbinectedin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lurbinectedin (PM01183) 4 mg vials of powder for concentrate for solution for infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lurbinectedin (PM01183)</intervention_name>
    <arm_group_label>A (lurbinectedin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntarily signed and dated informed consent

          -  Normal cardiac conduction and function (centrally read)

          -  Blood pressure between 90 and 150 mmHg systolic, inclusive, and not higher than 90
             mmHg diastolic.

          -  Specific serum electrolyte levels

        Exclusion Criteria:

          -  Age &gt; 65 years

          -  Performance status = 2 [Eastern Cooperative Oncology Group (ECOG)]

          -  Heart rhythm disturbances

          -  Significant ischemic coronary disease, heart failure, myocardial infarction, or
             unstable angina within the last six months.

          -  Prior exposure to anthracyclines at a cumulative dose of doxorubicin (or equivalent) &gt;
             450 mg/m²
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>1</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>2</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>5</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2015</study_first_submitted>
  <study_first_submitted_qc>May 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2015</study_first_posted>
  <last_update_submitted>September 21, 2016</last_update_submitted>
  <last_update_submitted_qc>September 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

